A single oral dose of a polyglucosamine influences the bioavailability of [9-14C]- Oleic acid in adult female Göttingen minipigs

BMC Obesity

Volumn 3, Issue 1, 2016, Pages

  Cnubben, Nicole H P ^a   Tel, Shanti L ^a   Hemmes, Marleen A ^a   Langenkamp Brand, Astrid ^a   Grossouw, Dimitri ^a   Jansen, Harm T ^a   de Bie, Bert T H J ^a  

^a TNO   (Netherlands)

Author keywords

Chitosan; Fat binding; Formoline L112; Obesity; Polyglucosamine; Weight management

Indexed keywords

CARBON 14; CHITOSAN; GLUCOSAMINE DERIVATIVE; OLEIC ACID; POLYGLUCOSAMINE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BODY WEIGHT MANAGEMENT; CONTROLLED STUDY; DRUG HALF LIFE; ENZYME ACTIVITY; FECES ANALYSIS; FEMALE; GOTTINGEN MINIPIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; OBESITY; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; VOLUME OF DISTRIBUTION;

EID: 85010841440     PISSN: None     EISSN: 20529538     Source Type: Journal    
DOI: 10.1186/S40608-016-0096-2     Document Type: Article

References (43)

1. World Health Organization, Obesity and overweight, Fact sheet N° 311, updated August 2014.
2. Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity Pharmacotherapy: New Drugs and Emerging Targets. Clin Pharmacol Ther. 2014;95(1):53-66.
3. Yun JW. Possible anti-obesity therapeutics from nature-A review. Phytochemistry. 2010;71:1625-41.
4. Cheung BMY, Cheung TT, Samaranayake NR. Safety of antiobesity drugs. Ther Adv Drug Saf. 2013;4(4):171-81.
5. Chaput JP, St-Pierre S, Tremblay A. Currently available drugs for the treatment of obesity: sibutramine and orlistat. Mini Rev Med Chem. 2007;7:3-10.
6. EMA, Refusal of the marketing authorisation for Qsiva (phentermine/topiramate) EMA/109958/2013, EMEA/H/C/002350, 21 February 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002350/WC500139215.pdf.
7. Froese WM, Ludlow ME. Efficacy of Over-the-Counter (OTC) Medical Device Products as a Tool in Clinical Weight Management. Food Nutr Sci. 2014;5: 1637-43.
8. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol. 2010;56:290-9.
9. Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev. 2010;62:3-11.
10. Rodriguez MS, Albertengo LE. Interaction between chitosan and oil under stomach and duodenal digestive chemical conditions. Biosci Biotechnol Biochem. 2005;69:2057-62.
11. Helgason T, Weiss J, McClements DJ, Gislason J, Einarsson JM, Thormodsson FR, Kristbergsson K. Examination of the interaction of chitosan and oil-inwater emulsions under conditions simulating the digestive system using confocal microscopy. J Aquat Food Prod Technol. 2008;17(3):216-33.
12. Han LK, Kimura Y, Okuda H. Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet. Int J Obes. 1999;23:174-9.
13. Dimzon IKD, Ebert J, Knepper TP. The interaction of chitosan and olive oil: effect of degree of deacetylation and degree of polymerization. Carbohydr Polym. 2013;92:564-70.
14. Dimzon IK, Knepper TP. Degree of deacetylation of chitosan by infrared spectroscopy and partial least squares. Int J Biol Macromol. 2015;72:939-45.
15. Jull AB, Ni Mhurchu C, Bennett DA, Dunshea-Mooij CA, Rodgers A. Chitosan for overweight or obesity. Cochrane Database Syst Rev. 2008;16(3):CD003892. doi:10.1002/14651858.CD003892.pub3.
16. Gades MD, Stern JS. Chitosan Supplementation and Fecal Fat Excretion in Men. Obes Res. 2003;11(5):683-8.
17. Tapola NS, Lyyra ML, Kolehmainen RM, Sarkkinen ES, Schauss AG. Safety aspects and cholesterol-lowering efficacy of chitosan tablets. J Am Coll Nutr. 2008;27(1):22-30.
18. Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind trial of chitosan for body weight reduction. Eur J Clin Nutr. 1999;53(5):379-81.
19. Mhurchu CN, Poppitt SD, McGill AT, Leahy FE, Bennett DA, Lin RB, Ormrod D, Ward L, Strik C, Rodgers A. The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes. 2004;28:1149-56.
20. Kaats GR, Michalek JE, Preuss HG. Evaluating efficacy of a chitosan product using a double-blinded, placebo controlled protocol. J Am Coll Nutr. 2006; 25(5):389-94.
21. Cornelli U, Belcaro G, Cesarone MR, Cornelli M. Use of polyglucosamine and physical activity to reduce body weight and dyslipidemia in moderately overweight subjects. Minerva Cardioangiol. 2008;56(5):71-8.
22. Egras AM, Hamilton WR, Lenz TL and Monaghan MS: An Evidence-Based Review of Fat Modifying Supplemental Weight Loss Products. J Obesity. 2011: 297-315, doi:10.1155/2011/297315.
23. Walsh AM, Sweeney T, Bahar B, O'Doherty JV. Multi-Functional Roles of Chitosan as a Potential Protective Agent against Obesity. Plos One. 2013; 8(1):e53828. doi:10.1371/journal.pone.0053828.
24. Pokhis K, Bitterlich N, Cornelli U, Cassano G. Efficacy of polyglucosamine for weight loss-confirmed in a randomized double-blind, placebo-controlled clinical investigation. BMC Obesity. 2015;2:25.
25. Karadeniz F, Kim SK. Antidiabetic Activities of Chitosan and Its Derivatives: A Mini Review. Adv Food Nutr Res. 2014;73:33-44.
26. Kokatnur MG, Oalmann MC, Johnson WD, Malcom GT, Strong JP. Fatty acid composition of human adipose tissue from two anatomical sites in a biracial community. Am J Clin Nutr. 1979;32(11):2198-205.
27. Spurlock ME, Gabler NK. The Development of Porcine Models of Obesity and the Metabolic Syndrome. J Nutr. 2008;138:397-402.
28. Christoffersen B, Golozoubova V, Pacini G, Svendsen O, Raun K. The young göttingen minipig as a model of childhood and adolescent obesity: Influence of diet and gender. Obesity. 2013;21(1):149-58.
29. Bode G, Clausing P, Gervais F, Loegsted J, Luft J, Nogues V, Sims J. The utility of the minipig as an animal model in regulatory toxicology. J Pharmacol Toxicol Meth. 2010;62:196-220.
30. Guilloteau P, Zabielski R, Hammon HM, Metges CC. Nutritional programming of gastrointestinal tract development. Is the pig a good model for man? Nutr Res Rev. 2010;23:4-22.
31. Patterson JK, Lei XG, Miller DD. The pig as an experimental model for elucidating the mechanisms governing dietary influence on mineral absorption. Exp Biol Med. 2008;233:651-64.
32. Wilfart A, Montagne L, Simmins H, Noblet J, Van Milgen J. Effect of fiber content in the diet on the mean retention time in different segments of the digestive tract in growing pigs. Livest Sci. 2007;109:27-9.
33. Van der Laan JW, Brightwell J, McAnulty P, Ratky J, Stark C. Under the auspices of the Steering Group of the RETHINK Project. J Pharmacol Toxicol Meth. 2010;62:184-95.
34. Stricker D. BrightStat.com: free statistics online. Comput. Methods Programs Biomed. 2008;92:135-43.
35. Pérez LY, Menéndez R, Más R, González RM. Plasma levels, tissue distribution and excretion of radioactivity after single-dose administration of (3H)-Oleic acid added to D-004, a lipid extract of the fruit of Roystonea regia in rats. Curr Ther Res. 2006;67(6):407-19.
36. Beierwaltes WH, Ice RD, Shaw MJ, Ryo UY. Myocardial uptake of labelled oleic and linoleic acids. J Nucl Med. 1975;16:842-5.
37. Pedersen NT. Estimation of assimilation of simultaneously ingested 14C-triolein and 3H-oleic acid as a test of pancreatic digestive function. Scand J Gastroenterol. 1984;19:161-6.
38. Liang H, Tantiwong P, Sriwijitkamol A, Shanmugasundaram K, Mohan S, Espinoza S, DeFronzo RA, Dubé JJ, Musi N. Effect of a sustained reduction in plasma free fatty acid concentration on insulin signalling and inflammation in skeletal muscle from human subjects. J Physiol. 2013;591(11):2897-909.
39. Boden G. Obesity and Free Fatty Acids (FFA). Endocrinol Metab Clin North Am. 2008;37(3):635-9.
40. Mani V, Harris AJ, Keating AF, Weber TE, Dekers JCM, Gabler NK. Intestinal integrity, endotoxin transport and detoxification in pigs divergently selected for residual feed intake. J Anim Sci. 2013;91(5):2141-50.
41. Piya MK, Harte AL, McTernan PG. Metbaoic endotoxaemia; is it more than just a gut feeling? (review). Curr Opin Lipidol. 2013;24(1):78-85.
42. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet-Induced Obesity and Diabetes in Mice. Diabetes. 2008;57:1470-81.
43. Zaved Waise TM, Toshinai K, Naznin F, NamKoong C, Abu Saleh Md Moin A, Sakoda H, Nakazato M. One-day high-fat diet induces inflammation in the nodose ganglion and hypothalamus of mice. Biochem Biophys Res Commun. 2015;464:1157-62.